4-Methoxy-5-[3-(2-methoxyphenyl)-2-oxopropyl]-6,6-dimethyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-6-ium

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 4-Methoxy-5-[3-(2-methoxyphenyl)-2-oxopropyl]-6,6-dimethyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-6-ium
• 英文别名: 1-(4-methoxy-6,6-dimethyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-6-ium-5-yl)-3-(2-methoxyphenyl)propan-2-one
• 化学式: C23H28NO5+
• 分子量: 398.5
• InChiKey: OWCHDURVQDTYDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Alzheimer's disease assay in a living patient
  申请人：Pain Therapeutics, Inc.

  公开号：US10222368B2

  公开（公告）日：2019-03-05

  An assay for Alzheimer's disease (AD) pathology in a living patient is disclosed wherein an amount of α7nAChR or TLR4 in a FLNA-captured protein complex or α7nAChR in an Aβ-captured protein complex or α7nAChR-FLNA, TLR4-FLNA and/or α7nAChR-Aβ42 complex present as a protein-protein complex in a sample is compared to the amount in a standard sample from a person free of AD pathology. An amount greater than in the standard sample indicates AD pathology. Also disclosed is an assay predictive of prognosis for treatment with a medicament in which the amount of an above protein or protein complex is compared to an amount in the presence of a medicament that binds to a FLNA pentapeptide and contains at least four pharmacophores of FIGS. 7-12. An amount of protein or protein complex determined in the presence of the medicament that is less than the first amount indicates a favorable treatment prognosis.

  本发明公开了一种活体患者阿尔茨海默病（AD）病理检测方法，其中将样品中FLNA捕获蛋白复合物中的α7nAChR或TLR4或Aβ捕获蛋白复合物中的α7nAChR或α7nAChR-FLNA、TLR4-FLNA和/或作为蛋白-蛋白复合物存在的α7nAChR-Aβ42复合物的量与无AD病理的人的标准样品中的量进行比较。如果含量大于标准样本中的含量，则表明存在 AD 病变。还公开了一种预测药物治疗预后的检测方法，其中将上述蛋白或蛋白复合物的量与存在与FLNA五肽结合并含有图7-12中至少四种药效团的药物时的量进行比较。如果在有药物存在的情况下测定的蛋白质或蛋白质复合物的量小于第一量，则表明治疗预后良好。
• ANALGESIA WITH MINIMAL TOLERANCE AND DEPENDENCE BY A MU OPIOID RECEPTOR AGONIST THAT ALSO BINDS FILAMIN A
  申请人：Wang Hoau-Yan

  公开号：US20090191579A1

  公开（公告）日：2009-07-30

  A composition and method are disclosed that utilize an isolated polypeptide or analog thereof to inhibit the interaction of a mu-opioid receptor with filamin A. A contemplated polypeptide has an amino acid residue sequence illustrated by the formula: W-[X 1 X 2 X 3 . . . X 43 X 44 X 45 ] n ValAlaX 48 GlyLeu[X 51 X 52 X 53 . . . X 94 X 95 X 96 ] m -Y, wherein the various elements are defined elsewhere. A contemplated method can be used to select a VAKGL-binding compound.
• NOVEL ANALGESIC THAT BINDS FILAMIN A
  申请人：Barbier Lindsay Burns

  公开号：US20100280061A1

  公开（公告）日：2010-11-04

  A compound, composition and method are disclosed that can bind to FLNA and provide analgesia. A contemplated compound has a structure that corresponds to Formula I, wherein R 1 and R 2 are substituents on W that is a ring structure, R 3 and R 4 are substituents on the depicted nitrogen atom, m, n and the dotted lines are all defined within.
• Alzheimer's Disease Assay in a Living Patient
  申请人：Pain Therapeutics, Inc.

  公开号：US20210389298A1

  公开（公告）日：2021-12-16

  An assay for Alzheimer's disease pathology (AD) in a living patient is disclosed wherein an amount of α7nAChR or TLR4 in a FLNA-captured protein complex or α7nAChR in an Aβ-captured protein complex or α7nAChR-FLNA, TLR4-FLNA and/or α7nAChR-Aβ 42 complex present as a protein-protein complex in a sample is determined and compared to the amount in a standard sample from a person free of AD pathology. An amount greater than in the standard sample indicates AD pathology. Also disclosed is an assay predictive of prognosis for treatment with a medicament in which the amount of an above protein or protein complex is determined and compared to an amount determined in the presence of a medicament that binds to a FLNA pentapeptide and contains at least four of the six pharmacophores of FIGS. 7 - 12 . An amount of protein or protein complex determined in the presence of the medicament less than the first determined amount indicates a favorable treatment prognosis.
• US8492349B2
  申请人：——

  公开号：US8492349B2

  公开（公告）日：2013-07-23